SEP
NBIX icon

Signature Equity Partners’s Neurocrine Biosciences NBIX Stock Holding History

Signature Equity Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.73K Buy
34
+24
+240% +$3.56K ﹤0.01% 958
2026
Q1 		$1.32K Hold
10
– – ﹤0.01% 1196
2025
Q4 		$1.42K Buy
+10
New +$1.45K ﹤0.01% 1312

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Signature Equity Partners's NBIX Position: Q2 2026 in Review

Signature Equity Partners increased its Neurocrine Biosciences (NBIX) stake by 240% in Q2 2026, buying an estimated $3.56K and bringing the position to 34 shares worth $5.73K. The position accounts for ﹤0.01% of the portfolio, ranked #958.

Signature Equity Partners first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 774 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Signature Equity Partners held 34 shares of Neurocrine Biosciences worth $5.73K as of Q2 2026.
  • Signature Equity Partners bought 24 Neurocrine Biosciences shares in Q2 2026, an estimated $3.56K.
  • Neurocrine Biosciences made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #958 holding.
  • Signature Equity Partners first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 774 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.